Literature DB >> 22169131

Usefulness of periprocedural bleeding to predict outcome after transcatheter aortic valve implantation.

Brian P Halliday1, Rafal Dworakowski, Beth Brickham, Olaf Wendler, Philip MacCarthy.   

Abstract

Bleeding is a known predictor of poor outcome after a number of cardiac interventions. We investigated whether using the new bleeding definition of the Valve Academic Research Consortium predicts a poor outcome after transcatheter aortic valve implantation. In addition, we sought to identify those patient characteristics that predict periprocedural bleeding and investigated the effect of blood transfusion. This was a retrospective study of 101 patients undergoing transapical or transfemoral transcatheter aortic valve implantation at Kings College Hospital from August 2007 to November 2010. The association among bleeding, blood transfusion, and in-hospital and 6-month mortality was examined. Of the 101 patients, 5 (4.9%) had life-threatening periprocedural bleeding related to vascular or apical complications, 17 (17%) had major bleeding, and 79 (78%) had minor or no bleeding. The in-hospital mortality rate for the cohort was 9.9% (n = 10) and the 6-month mortality rate was 18.8% (n = 19). Those patients with life-threatening bleeding and those who were transfused had significantly greater in-hospital mortality rates than the patients without life-threatening bleeding or transfusion (60.0% vs 7.3%, p <0.05; and 14.8% vs 4.3%, p <0.05, respectively). Life-threatening bleeding, a decrease in hemoglobin >5 g/dl, and a blood transfusion of >2 U were associated with increased mortality at 6 months. In a logistic regression model, coexisting vascular disease, diabetes, and preprocedural anemia significantly affected the incidence of life-threatening or major bleeding. In conclusion, consistent with many other cardiac interventions, life-threatening periprocedural bleeding after transcatheter aortic valve implantation is associated with poorer outcomes. Copyright Â
© 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22169131     DOI: 10.1016/j.amjcard.2011.10.034

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  5 in total

1.  Thromboinflammatory response and predictors of outcomes in patients undergoing transcatheter aortic valve replacement.

Authors:  Travis R Sexton; Eric L Wallace; Amy Chen; Richard J Charnigo; Hassan K Reda; Khaled M Ziada; John C Gurley; Susan S Smyth
Journal:  J Thromb Thrombolysis       Date:  2016-04       Impact factor: 2.300

2.  Prophylactic intraoperative tranexamic acid administration and postoperative blood loss after transapical aortic valve implantation.

Authors:  Navid Madershahian; Maximilian Scherner; Roman Pfister; Tanja Rudolph; Antje C Deppe; Ingo Slottosch; Elmar Kuhn; Yeong-Hoon Choi; Thorsten Wahlers
Journal:  J Cardiothorac Surg       Date:  2015-03-28       Impact factor: 1.637

3.  Antithrombotic therapy - predictor of early and long-term bleeding complications after transcatheter aortic valve implantation.

Authors:  Katarzyna Czerwińska-Jelonkiewicz; Adam Witkowski; Maciej Dąbrowski; Marek Banaszewski; Ewa Księżycka-Majczyńska; Zbigniew Chmielak; Krzysztof Kuśmierski; Tomasz Hryniewiecki; Marcin Demkow; Ewa Orłowska-Baranowska; Janina Stępińska
Journal:  Arch Med Sci       Date:  2013-12-26       Impact factor: 3.318

4.  Vascular complications after transcatheter aortic valve implantation (TAVI): risk and long-term results.

Authors:  Katarzyna Czerwińska-Jelonkiewicz; Ilona Michałowska; Adam Witkowski; Maciej Dąbrowski; Ewa Księżycka-Majczyńska; Zbigniew Chmielak; Krzysztof Kuśmierski; Tomasz Hryniewiecki; Marcin Demkow; Janina Stępińska
Journal:  J Thromb Thrombolysis       Date:  2014-05       Impact factor: 2.300

5.  Antithrombotic therapy in patients undergoing TAVI: an overview of Dutch hospitals.

Authors:  V J Nijenhuis; P R Stella; J Baan; B R G Brueren; P P de Jaegere; P den Heijer; S H Hofma; P Kievit; T Slagboom; A F M van den Heuvel; F van der Kley; L van Garsse; K G van Houwelingen; A W J Van't Hof; J M Ten Berg
Journal:  Neth Heart J       Date:  2014-02       Impact factor: 2.380

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.